Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients

J Crohns Colitis. 2022 Jun 24;16(5):863-864. doi: 10.1093/ecco-jcc/jjab207.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Infliximab / therapeutic use
  • Treatment Outcome

Substances

  • Gastrointestinal Agents
  • Infliximab